海思科：创新药HSK39297片新适应症获药物临床试验批准

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of its innovative drug HSK39297, aimed at treating age-related macular degeneration (AMD) [1] Company Summary - HSK39297 is an innovative drug developed by the company, specifically targeting age-related macular degeneration [1] - The drug has a clear target, proven efficacy, and good safety profile, which may address existing challenges in clinical treatment options for AMD [1] Industry Summary - In 2015, the prevalence of AMD in China was approximately 5.2%, affecting nearly 26.65 million people, with projections indicating nearly 300 million cases by 2040 [1] - Current treatment options for AMD are limited, highlighting the potential market opportunity for new therapies like HSK39297 [1]